BioWorld

July 30, 2002

BioMarin, Genzyme Complete Rolling BLA For Aldurazyme

As promised, BioMarin Pharmaceutical Inc. put the finishing touches on its rolling biologics license application for Aldurazyme, the enzyme replacement therapy for mucopolysaccharidosis I. (BioWorld Today) Read More

ZymoGenetics, Wyeth Enter Deal Around IL-13 Cytokine Receptor

Muscarinic Receptor, Derived From Deadly Mushroom, Retains Opiate Analgesia, Sans Addiction

FDA Considers Policy To Add Bar Codes To Drugs, Devices

Durect, Voyager Collaborate To Develop Alzheimer's Treatment

Protarga To Work With ICOS On Targaceutical Cancer Drugs

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...